ReviewJournal of nanobiotechnology2026
Engineered live bacteria for liver diseases and gut-liver axis disorders: from genetic modification to advanced delivery systems.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut-Liver Translocation of Bacteroides Uniformis Alleviates Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease by Suppressing Hepatocyte Ferroptosis via Propionic Acid Secretion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Liver diseases, including hepatocellular carcinoma (HCC), non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD), impose a significant global health burden, with over 2 million deaths annually and substantial economic losses. Current treatments, primarily pharmacological, face challenges such as insufficient efficacy, poor absorption, and drug resistance. The liver-gut axis, a critical pathway linking the liver and intestines, offers a therapeutic target for these diseases. Engineered live bacteria, modified through genetic engineering and synthetic biology, have emerged as a promising alternative. These bacteria can be designed to deliver therapeutic agents directly to the liver or gut, enhancing efficacy and reducing systemic side effects. This review explores the application of engineered live bacteria in treating liver diseases, focusing on strains such as Bifidobacterium, Escherichia coli Nissle 1917 (EcN), Bacillus subtilis (B. subtilis), Saccharomyces boulardii (S. boulardii), and Lactobacillus reuteri (L. reuteri). It also pays attention to the internal genetic modification and external covalent connection of the original live bacteria. We discuss the design of dosage forms, including capsule formulations, microencapsulation, and nanopreparations, and administration methods like oral and in situ injection. Additionally, we address the challenges and future prospects of using engineered live bacteria to target liver diseases and related conditions, aiming to advance their clinical application and reduce the global burden of liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.